Approximately one in three people diagnosed with major depressive disorder fails to respond to two or more antidepressant trials at adequate dose and duration — a threshold that defines treatment-resistant depression, one of the most undertreated conditions in psychiatry. For patients in Jacksonville and the broader Northeast Florida region who have exhausted standard options, IV ketamine therapy represents a clinically distinct pathway, one that operates through a fundamentally different mechanism and has demonstrated rapid onset of action in peer-reviewed research. At Ketamine Wellness Institute Jacksonville, we provide IV ketamine therapy under direct physician supervision, and we want patients to have a clear, evidence-based understanding of what this treatment involves before they seek a consultation.
What Is Treatment-Resistant Depression?
Treatment-resistant depression is not simply “depression that is hard to treat.” It has a specific clinical meaning: failure of at least two antidepressant trials, each at an adequate dose for an adequate duration — generally eight to twelve weeks — without achieving remission. Patients who meet this definition have often been cycling through medications for years, experiencing partial responses, intolerable side effects, or no benefit at all. The emotional exhaustion that accompanies this cycle is real, and it compounds the underlying illness. Understanding that treatment resistance has a specific clinical definition and a specific clinical pathway is one of the first things we want patients to know.
If you’d like a broader overview of depression treatment options available in Jacksonville, FL, our dedicated conditions page outlines the approaches we offer and who may be a candidate.
How IV Ketamine Works: A Different Mechanism
IV ketamine works differently from every antidepressant in the standard psychiatric formulary. Where SSRIs, SNRIs, MAOIs, and tricyclics all operate on monoamine neurotransmitter systems — serotonin, norepinephrine, dopamine — ketamine acts primarily on NMDA receptors within the glutamate system, which governs the brain’s primary excitatory signaling. By blocking NMDA receptors in a dose-dependent way, ketamine triggers a rapid increase in synaptic glutamate, followed by activation of AMPA receptors and downstream stimulation of BDNF and mTOR pathways that promote synaptogenesis — the growth of new synaptic connections. This is the leading explanation for why many patients report relief within hours or days of their first infusion, rather than the weeks required by monoamine-based antidepressants. Research published by the National Institute of Mental Health and in journals including JAMA Psychiatry has supported this rapid-onset mechanism repeatedly.
For a deeper look at the science behind ketamine infusions and how they work, we’ve published a detailed overview that walks through the neuroscience in accessible terms.
Physician Supervision at Ketamine Wellness Institute Jacksonville
At Ketamine Wellness Institute Jacksonville, every infusion is administered under the direct supervision of Dr. Aravind Reddy, MD — a double board-certified anesthesiologist and interventional pain medicine specialist who completed his fellowship in pain management at the University of North Carolina in Chapel Hill. Dr. Reddy’s dual board certification is directly relevant to IV ketamine care: anesthesiology training provides deep expertise in intravenous drug delivery, pharmacokinetics, cardiovascular and respiratory monitoring, and the management of sedative and dissociative agents. Pain medicine fellowship training adds specific experience with complex, medically refractory patients. Dr. Reddy provides direct physician oversight at every session, which means he is not signing off from a distance — he is present.
FDA Status: What Patients Need to Understand
We want to address clearly the question of FDA status, because patients encounter conflicting information online. The psychiatric use of IV ketamine for depression — including treatment-resistant depression — is off-label. Ketamine is an FDA-approved anesthetic agent, but its use for psychiatric indications has not received FDA approval through a New Drug Application for those indications. This is not unusual in medicine; many effective, widely used treatments carry off-label status. What matters is that the evidence base for IV ketamine in treatment-resistant depression is robust, including multiple randomized controlled trials and meta-analyses. SPRAVATO® (esketamine nasal spray) is a related but distinct compound that holds FDA approval specifically for treatment-resistant depression — it is not the same as IV ketamine, and we do not offer SPRAVATO® at our clinic. Discuss with your provider how these distinctions should inform your treatment decisions.
Cost and Insurance: A Transparent Conversation
One barrier that prevents many qualified patients from pursuing IV ketamine is uncertainty about cost and the lack of insurance coverage. Because the psychiatric use of IV ketamine is off-label, reimbursement through most commercial insurance plans is unlikely, and patients should approach the consultation expecting to discuss out-of-pocket costs directly with our team. We believe transparency here is essential: the financial reality of ketamine therapy is a meaningful consideration, and we want patients to have an honest conversation about it from the first interaction rather than discovering costs late in the intake process. Results vary by individual, and we do not believe that withholding financial information serves patients.
For detailed pricing information, visit our ketamine therapy pricing page to review current rates and what is included in your care.
What to Expect During a Ketamine Infusion
The second barrier we frequently encounter is the question of what happens during the infusion — particularly the dissociative experience that many patients have read about. The perceptual shifts associated with a ketamine infusion, including altered time perception, mild visual changes, and a sense of disconnection from ordinary thought patterns, are real and unfamiliar. For patients who have never had a dissociative experience and whose primary relationship with altered states is anxiety about them, this can feel like a significant obstacle. We address this directly: our intake process includes a thorough pre-infusion discussion of what to expect, what our clinical staff is monitoring, and what to do if the experience feels uncomfortable. Dr. Reddy’s direct presence throughout each session means that any clinical concerns are addressed immediately by a physician with advanced training in managing sedative and dissociative agents.
Our blog post on ketamine infusion therapy for depression: what to expect walks through the session experience step by step and is a helpful read before your first appointment.
Treatment Protocol: Number of Sessions
A standard initial course of IV ketamine for treatment-resistant depression typically consists of six infusions completed over two to three weeks, following the protocol studied in the foundational clinical research. Ongoing maintenance infusions — the frequency of which depends on the individual’s response — may be recommended after the initial series. We assess each patient’s response carefully and have a clinical conversation about whether and when additional sessions are indicated. Discuss with your provider what a realistic maintenance plan looks like given your history, current response, and overall care goals.
Frequently Asked Questions
How quickly does IV ketamine work for depression?
Many patients report noticeable mood improvement within hours to days of the first infusion — a speed that is clinically unusual and reflects ketamine’s distinct mechanism compared to traditional antidepressants. The full benefit of the initial infusion series typically becomes apparent over two to three weeks. Results vary by individual, and not all patients experience the same degree or speed of response.
Is IV ketamine FDA-approved for depression?
No. IV ketamine’s use for depression, including treatment-resistant depression, is off-label — not FDA-approved for this indication. The evidence base is substantial and includes multiple peer-reviewed clinical trials, but it has not gone through the FDA drug approval process for psychiatric indications. SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression but is a different compound and not available at our clinic.
Who performs the ketamine infusion at your Jacksonville clinic?
Every infusion at Ketamine Wellness Institute Jacksonville is performed under the direct supervision of Dr. Aravind Reddy, MD, a double board-certified anesthesiologist and interventional pain medicine specialist. Dr. Reddy is physically present during every session, providing physician-level oversight of the infusion and monitoring throughout.
How many IV ketamine sessions are needed?
The standard induction protocol studied in clinical research is six infusions over approximately two to three weeks. After the induction series, the need for maintenance infusions depends on each patient’s individual response and clinical picture. Discuss with Dr. Reddy what a realistic ongoing treatment plan looks like for your specific situation.
Can IV ketamine be combined with antidepressants I’m already taking?
This is a clinical question that depends on your specific medications. Certain drugs may interact with ketamine or affect its efficacy. Our intake evaluation includes a full medication review, and Dr. Reddy will advise on any necessary adjustments before the first session. Do not modify your medications without discussing it with your prescriber and our team first.
Key Takeaways
- Treatment-resistant depression has a specific clinical definition — failure of at least two antidepressant trials — and IV ketamine represents a distinct mechanistic alternative.
- Ketamine acts on NMDA glutamate receptors, producing rapid synaptogenesis and fast-onset relief that is mechanistically different from all monoamine-based antidepressants.
- IV ketamine for psychiatric indications is off-label; the evidence base is robust, but FDA approval has not been granted for these uses.
- Every infusion at Ketamine Wellness Institute Jacksonville is conducted under direct supervision of Dr. Aravind Reddy, MD.
- Results vary by individual; discuss cost, expectations, and your full clinical history with your provider before beginning treatment.
Conclusion
Treatment-resistant depression deserves more than another prescription for a medication that operates the same way as the last five. IV ketamine offers a different mechanism, a different pharmacological profile, and a different clinical experience — and when delivered under direct physician supervision by a specialist with the right training, it can open a door that years of standard treatment could not. If you are in the Jacksonville area and have not responded to antidepressant treatment, schedule a consultation with Dr. Reddy at Ketamine Wellness Institute Jacksonville today.
About Dr. Aravind Reddy, MD
Dr. Aravind Reddy is a double board-certified anesthesiologist and interventional pain medicine specialist who leads Ketamine Wellness Institute Jacksonville. He completed his residency and fellowship in pain management at the University of North Carolina in Chapel Hill. Born and raised in Tallahassee, Florida, Dr. Reddy returned to North Florida to serve the Jacksonville community. He is committed to compassionate, multi-disciplinary care for patients with complex pain and mental health conditions, providing direct physician oversight at every ketamine infusion session. The clinic operates from Jacksonville Beach and serves patients across the Northeast Florida region.
References
National Institute of Mental Health — https://www.nimh.nih.gov/health/topics/depression
American Psychiatric Association — https://www.psychiatry.org/patients-families/depression/what-is-depression
American Society of Ketamine Physicians, Psychotherapists & Practitioners — https://www.askp3.org/
Mayo Clinic — https://www.mayoclinic.org/diseases-conditions/treatment-resistant-depression/symptoms-causes/syc-20377944
Medical Disclaimer
The content of this article is provided by Ketamine Wellness Institute Jacksonville for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Ketamine’s use in psychiatric conditions is off-label and not FDA-approved for those indications. Individual results vary. Always discuss treatment options, risks, and benefits with a qualified healthcare provider before making any medical decisions.